Drugs / Bermekimab
Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05252520 | May → Nov 2023 | — | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
| Phase 1 | NCT04544826 | Oct 2020 → Aug 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04544813 | Oct 2020 → May 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03207724 | Oct 2017 → Nov 2019 | hypoproteinemia, hypercatabolic, pancreatic ductal adenocarcinoma | Andrew Hendifar, MD | Completed | No outcome recorded |
| Phase 1 | NCT03047317 | Feb → Mar 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01260545 | Apr 2011 → Jun 2012 | hematopoietic and lymphoid cell neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01021072 | Mar 2010 → Oct 2012 | high grade malignant neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT04988308 | Oct 2021 → Oct 2022 | hidradenitis suppurativa | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT04990440 | Sep 2021 → Mar 2022 | atopic eczema | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT04791319 | May 2021 → Feb 2022 | atopic eczema | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT04021862 | Oct 2019 → Jun 2020 | atopic eczema | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04019041 | Sep 2019 → May 2020 | hidradenitis suppurativa | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04045743 | Jul 2019 → Jan 2021 | systemic sclerosis | Hellenic Institute for the Study of Sepsis | Completed | No outcome recorded |
| Phase 2 | NCT03512275 | Jun 2018 → Jan 2019 | hidradenitis suppurativa | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03496974 | May → Dec 2018 | atopic eczema | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01965613 | Jan 2014 → Dec 2016 | pyoderma gangrenosum | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01474798 | Feb → Oct 2012 | acne | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01384630 | Sep 2011 → Jul 2012 | psoriasis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01427699 | Jun 2011 → Oct 2012 | type 2 diabetes mellitus | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01270945 | Jun 2011 → Sep 2013 | peripheral arterial occlusive disease 1 | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01767857 | Mar 2013 → Jun 2017 | colorectal cancer | Janssen Research & Development, LLC | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02643654 Comparator | Dec 2015 → Oct 2016 | hidradenitis suppurativa | Evangelos J. Giamarellos-Bourboulis, M.D. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02138422 Comparator | Jul 2014 → Nov 2015 | colorectal cancer | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bermekimab | “Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma.” PMID 36056179 ↗ Sep 2022 |
| Known as | CA-18C3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01260545 ↗ |
| Known as | CV-18C3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01270945 ↗ |
| Known as | JNJ-77474462 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04544813 ↗ |
| Known as | MABp1 | “Bermekimab (MABp1) is a first-in-class true human monoclonal antibody cloned directly from human B lymphocytes that specifically targets and neutralizes IL-1α.” NCT04045743 ↗4“A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis” NCT03496974 ↗ |
| Known as | RA-18C3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01474798 ↗ |
| Known as | T2-18C3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01427699 ↗ |
| Known as | Xilonix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02138422 ↗ |
| Action | Inhibit | “We aimed to assess the safety and tolerability of MABp1 for interleukin-1α blockade in a refractory cancer population.” PMID 24746841 ↗ Apr 2014 |
| Modality | Monoclonal antibody | “We used a first-in-class, monoclonal antibody (MABp1) cloned from a human being to target interleukin-1α” PMID 24746841 ↗ Apr 2014 |
| Route | Intravenous | “Patients received MABp1 intravenously once every 3 weeks” PMID 24746841 ↗ Apr 2014 |
| Target | IL1A | “MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers” PMID 24746841 ↗ Apr 2014 |